Evaluation of the combination of brentuximab vedotin and chemotherapy in peripheral CD30 + T lymphomas: controlled, randomized, double-blind trial

被引：0
|
作者：
Charlotte, Berthoux
Laure, Farnault
Geoffroy, Venton
机构：
来源：
HEMATOLOGIE | 2019年 / 25卷 / 02期
关键词：
D O I：
10.1684/hma.2019.1459
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：65 / 65
页数：1
相关论文
共 50 条
  • [41] Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
    Herrera, Alex F.
    Zain, Jasmine
    Savage, Kerry J.
    Feldman, Tatyana
    Brammer, Jonathan E.
    Chen, Lu
    Puverel, Sandrine
    Popplewell, Leslie
    Budde, Lihua Elizabeth
    Mei, Matthew
    Hosing, Chitra
    Nair, Ranjit
    Leslie, Lori
    Daniels, Shari
    Peters, Lacolle
    Forman, Stephen
    Rosen, Steven
    Kwak, Larry
    Iyer, Swaminathan P.
    Haematol, Lancet
    LANCET HAEMATOLOGY, 2024, 11 (09): : e671 - e681
  • [42] BRENTUXIMAB VEDOTIN IN THE TREATMENT OF RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T-CELL LYMPHOMA PATIENTS: A PHASE 2 STUDY OF THE FONDAZIONE ITALIANA LINFOMI
    Carella, M.
    Pellegrini, C.
    Corradini, P.
    Orsucci, L.
    Volpetti, S.
    Argnani, L.
    Dodero, A.
    Stefoni, V.
    Zinzani, P. L.
    HAEMATOLOGICA, 2021, 106 (10) : 70 - 70
  • [43] Melatonin in Patients with Cancer Receiving Chemotherapy: A Randomized, Double-blind, Placebo-controlled Trial
    Sookprasert, Aumkhae
    Johns, Nutjaree Pratheepawanit
    Phunmanee, Anakapong
    Pongthai, Parichart
    Cheawchanwattana, Areewan
    Johns, Jeff
    Konsil, Julraht
    Plaimee, Preeyaporn
    Porasuphatana, Supatra
    Jitpimolmard, Suthiphan
    ANTICANCER RESEARCH, 2014, 34 (12) : 7327 - 7337
  • [44] Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    Duvic, Madeleine
    Tetzlaff, Michael
    Clos, Audra L.
    Gangar, Pamela
    Talpur, Rakhshandra
    BLOOD, 2012, 120 (21)
  • [45] B vitamins and their combination could reduce migraine headaches: A randomized double-blind controlled trial
    Nematgorgani, Shiva
    Razeghi-Jahromi, Soodeh
    Jafari, Elham
    Togha, Mansoureh
    Rafiee, Pegah
    Ghorbani, Zeinab
    Ahmadi, Zeynab Sadat
    Baigi, Vali
    CURRENT JOURNAL OF NEUROLOGY, 2022, 21 (02): : 105 - 118
  • [46] CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors
    Heiser, Ryan A.
    Grogan, Bryan M.
    James, Reice D.
    Ulrich, Michelle L.
    Berndt, Jason D.
    O'Connor, Brian P.
    Gardai, Shyra J.
    Lu, Hailing
    Knowles, Scott M.
    CANCER RESEARCH, 2023, 83 (07)
  • [47] Citalopram, Methylphenidate, or Their Combination in Geriatric Depression: A Randomized, Double-Blind, Placebo-Controlled Trial
    Lavretsky, Helen
    Reinlieb, Michelle
    St Cyr, Natalie
    Siddarth, Prabha
    Ercoli, Linda M.
    Senturk, Damla
    AMERICAN JOURNAL OF PSYCHIATRY, 2015, 172 (06): : 561 - 569
  • [48] Remimazolam versus propofol in combination with esketamine for surgical abortion: A double-blind randomized controlled trial
    Yue, Linli
    Ma, Xiaoling
    Li, Na
    Chen, Jing
    Wang, Jun
    Wan, Zhenzhen
    Yang, Lin
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (09): : 1606 - 1616
  • [49] A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine
    Keskinbora, Kader
    Aydinli, Isik
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2008, 110 (10) : 979 - 984
  • [50] BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP
    Fanale, M. A.
    Horwitz, S. M.
    Forero-Torres, A.
    Bartlett, N. L.
    Advani, R. H.
    Pro, B.
    Chen, R. W.
    Davies, A.
    Illidge, T.
    Huebner, D.
    Kennedy, D. A.
    Shustov, A. R.
    ANNALS OF ONCOLOGY, 2014, 25
12345